Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma

Future Oncology

Volumn 4, Issue 2, 2008, Pages 169-177

  Perz, Jolanta B ^a   Ho, Anthony D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute myeloid leukemia; AML; Histamine; IFN ; IL 2; Malignant melanoma; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ASTEMIZOLE; CANCER VACCINE; DACARBAZINE; DIPHENHYDRAMINE; FLT3 LIGAND; HISTAMINE; HISTAMINE H2 RECEPTOR; INTERLEUKIN 2; MAXAMINE; PROTEIN KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR RECEPTOR; TERFENADINE; TRIPROLIDINE; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HEALTH ECONOMICS; HEART PALPITATION; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKEMIA RELAPSE; LIVER METASTASIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MELANOMA; MONOCYTE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACODYNAMICS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RIGOR; SIDE EFFECT; SOLID TUMOR; STOMATITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; ANIMAL; DOSE RESPONSE; KIDNEY TUMOR; NEOPLASM; PHYSIOLOGY; REVIEW; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; MELANOMA; NEOPLASMS; RECEPTORS, HISTAMINE H2; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 43049119363     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.2.169     Document Type: Article

References (22)

1. Hellstrand K, Hermodsson S: Synergistic NK cell activation by histamine and interleukin-2. Int. Arch. Allergy Appl. Immunol. 92, 379-389 (1990).
2. Hellstrand K, Asea A, Dahlgren C, Hermodsson S: Histaminergic regulation of NK-cells: role of monocyte-derived, reactive oxygen metabolites. J. Immunol. 153, 4940-4947 (1994).
3. Hellstrand K, Naredi P, Lindner P et al.: Histamine in immunotherapy of advanced melanoma. A pilot study. Cancer Immunol. Immunother 39, 416-419 (1994).
4. Hellstrand K. Asea A, Hermodsson S: Role of histamine in natural killer cell-mediated resistance against tumor cells. J. Immunol. 145, 4365-4370 (1990).
5. Johansson S. Landstrom M, Hellstrand K, Henriksson R: The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br. J. Cancer 77, 1213-1219 (1998).
6. Wotherspoon HA, Anderson JR, Morran CG, Murray GD, McArdle CS: Randomised controlled trial of an - H2-receptor antagonist in gastric cancer. Br. J. Surg. 84, 1168-1169 (1997).
7. Lynch NR, Salomon JC: Passive local anaphylaxis: demonstration of antitumour activity and complementation of intratumour BCG. J. Natl. Cancer Inst. 58, 1093-1098 (1977).
8. Tatsuta M, Iishi H, Ichii M, Noguchi S. Yamamura H. Taniguchi H: Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methy-N-nitro-N-nitrosoguanidine. J. Natl Cancer Inst. 76, 277-281 (1986).
9. Suonio E, Tuornisto L, Alhava E: Effects of histamine, H1, H2, Hic receptor antagonists and α-fluoromethyhistidine on the growth of human colorectal cancer in the subrenal capsule assays. Agents Actions 41, 118-120 (1994).
10. Brunda MJ, Bellantoni D, Sulich V: In vivo anti-tumour activity of combinations of INF-α and interleukin-2 In a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer 40, 365-441 (1987).
11. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K: NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur. J. Haematol. 57, 312-319 (1996).
12. Hellstrand K, Mellqvist UH, Wallhult E et al.: Histamine and interleukin-2 in acute myelogenous leukemia. Leuk. Lymphoma 27, 429-438 (1997).
13. Middleton M, Sarno M, Agarwala SS et al.: Pharmacokinetics of histamine dibydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J. Clin. Pharmacol. 42, 774-781 (2002).
14. Donskov F, Middleton M. Fode K et al.: Two randomised Phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br. J. Cancer 93, 757-762 (2005).
15. Donskov F, Hokland M, Marcussen N, Torp Madsen HH, von der Maase H: Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma - results from a randomised Phase II trial. Br. J. Cancer 94, 218-226 (2006).
16. Atkins MB, Lotze MT, Dutcher JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
17. Hellstrand K, Hermodsson S, Brune M, Naredi P, Carneskog J, Mellqvist UH: Histamine in cancer immunotherapy. Scand. J. Clin. Lab. Invest. 57, 193-202 (1997).
18. Keilholz U: Biochemotherapy of melanoma. Forum (Genova) 13, 158-165 (2003).
19. Agarwala SS, Glaspy J, O'Day SJ et al.: Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 20, 125-133 (2002).
20. Asernissen AM, Scheibenbogen C, Letsch A et al.: Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomised clinical trial of Interleukin 2 with or without histamine (MP 104). Clin. Cancer Res. 11, 290-297 (2005).
21. Brune M, Castaigne S. Catalano J et al.: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomised Phase 3 trial. Blood 108, 88-96 (2006).
22. Galmarini CM: Histamine dihydrochloride (subcutaneous) Maxim. Curr. Opin. Investig. Drugs 5, 1298-1310 (2004).